CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Experimental Group +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04088227
NCT04088227Phase 2Completed

Effect of Platelet Rich Plasma Injections on Inflammatory and Chondrodegenerative Biomarkers in Patients With Acute Anterior Cruciate Ligament Tears

Andrews Research & Education Foundation·interventional·Posted Sep 12, 2019·Updated Feb 17, 2025

In Brief

A Phase 2 clinical trial evaluating Experimental Group and Control Group for Anterior Cruciate Ligament Tear and Anterior Cruciate Ligament Rupture. Completed, enrolled 24 participants across 1 site.

Detailed Summary

A potential long-term consequence of anterior cruciate ligament injuries is the development of post-traumatic osteoarthritis in the years following injury. There are no curative treatments for osteoarthritis, increasing the importance of minimizing the occurrence of post-traumatic osteoarthritis following anterior cruciate ligament injuries. Current literature has begun to indicate that biochemical changes in the knee joint cartilage, such as chondrocyte death, following injury can contribute to the development of post-traumatic osteoarthritis. The main objective of this study is to determine if an early intervention of joint aspiration and platelet rich plasma injection will positively affect the biomarkers representative of chondral degeneration in patients with anterior cruciate ligament injuries. We hypothesize that the intervention will reduce the volume of inflammatory and chondrodegenerative biomarkers following anterior cruciate ligament injury.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 12, 2019
Enrollment StartSep 12, 2019
Primary CompletionSep 1, 2022
Study CompletionApr 21, 2023
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 6.8 years ago

Interventions

Experimental Groupdrug

Patients will receive platelet rich plasma injection two times prior to surgery.

Control Groupother

Patients will have their knee aspirated at their initial physician visit and at the time of surgery.